Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Classical hematology 1Breast 1

Conditions

Ovarian Neoplasms 92Fallopian Tube Neoplasms 25Breast Neoplasms 21Endometrial Neoplasms 19Carcinoma, Ovarian Epithelial 12Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Neoplasms 6Fanconi Anemia, Complementation Group D1 5Uterine Cervical Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 3Uterine Neoplasms 2Stomach Neoplasms 2Peritoneal Neoplasms 2Ovarian Diseases 2Carcinosarcoma 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Relapsed Ovarian Cancers Patients 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Platinum-sensitive Ovarian Cancer 1Platinum-Refractory Fallopian Tube Carcinoma 1

Interventions

Fulvestrant 2serabelisib 1sapanisertib 1ribociclib 1palbociclib 1olaparib 1niraparib 1inavolisib 1exemestane 1capivasertib 1abemaciclib 1Tamoxifen 1STX-478 1Paclitaxel 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1CYH33 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × olaparib × Gynecologic × Clear all
NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡